Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
| العنوان: | Challenges in the management of advanced, ER-positive, HER2-negative breast cancer |
|---|---|
| المؤلفون: | Luca Malorni, Laura Biganzoli, Angelo Di Leo, Ilenia Migliaccio, Cristina Guarducci, Christopher D. Hart |
| المصدر: | Nature Reviews Clinical Oncology. 12:541-552 |
| بيانات النشر: | Springer Science and Business Media LLC, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Oncology, Gynecology, medicine.medical_specialty, Everolimus, Antineoplastic Agents, Hormonal, Tumour heterogeneity, Receptor, ErbB-2, business.industry, HER2 negative, Breast Neoplasms, Context (language use), Disease, medicine.disease, Optimal management, Breast cancer, Receptors, Estrogen, Internal medicine, medicine, Humans, Female, Neoplasm Metastasis, Stage (cooking), business, medicine.drug |
| الوصف: | Hormone-receptor-positive breast cancer accounts for the majority of all breast cancers. The evolution of this disease from early stage to the metastatic setting leads to increased heterogeneity and the development of treatment resistance representing a great challenge for management decisions. In this Review, we examine the current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer, discuss how to tackle these therapeutic challenges and provide suggestions for the optimal management of this patient population. Hormone-receptor-positive breast cancer accounts for the majority—up to 80%—of all breast cancers. The evolution of breast cancer from early stage to the metastatic setting leads to increased heterogeneity, the occurrence of new mutations, and the development of treatment resistance representing a great challenge for management decisions. Unfortunately, little data exist to offer guidance in this context, and a reliance on traditional clinical parameters remains when deciding on optimal treatment. In advanced-stage oestrogen receptor-positive (ER+) disease, ongoing issues include the choice between endocrine therapy and chemotherapy, the appropriate sequence of treatment agents, and the incorporation of biological agents, such as everolimus, into the treatment armamentarium. In metastatic disease, repeated biopsies can help to reassess the receptor or genetic mutational status; however, the evidence to support this approach is limited. In this Review, we examine the current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer, discuss how to tackle these therapeutic challenges and provide suggestions for the optimal management of this patient population. |
| تدمد: | 1759-4782 1759-4774 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2c19ee765e3234a62b7bbc65c7e4edTest https://doi.org/10.1038/nrclinonc.2015.99Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2d2c19ee765e3234a62b7bbc65c7e4ed |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17594782 17594774 |
|---|